AIM
SRPT icon

Advantage Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

Advantage Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-200
Closed -$11K – 1056
2017
Q4 		$11K Hold
200
– – ﹤0.01% 674
2017
Q3 		$9K Buy
+200
New +$7.99K ﹤0.01% 722
2016
Q3 		– Sell
-150
Closed -$3K – 958
2016
Q2 		$3K Buy
+150
New +$2.78K ﹤0.01% 758

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Advantage Investment Management's SRPT Position: Q1 2018 in Review

Advantage Investment Management sold out of Sarepta Therapeutics (SRPT) in Q1 2018, closing a stake of 200 shares — an estimated $11K sold.

Advantage Investment Management first reported a position in SRPT in Q2 2016 and held it in 3 quarters. The position peaked at $11K in Q4 2017. 269 funds tracked by Wall St. Rank hold SRPT as of Q1 2018.

  • Advantage Investment Management reported no remaining Sarepta Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Advantage Investment Management sold 200 Sarepta Therapeutics shares in Q1 2018, an estimated $11K.
  • Advantage Investment Management first reported a position in Sarepta Therapeutics in Q2 2016 and held it in 3 quarters.
  • Advantage Investment Management's Sarepta Therapeutics position peaked at $11K in Q4 2017.
  • 269 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2018.

Based on Advantage Investment Management's 13F filing for Q1 2018, filed 15 May 2018.